66PAdapting a prescreening program to match molecular alterations in over 5,000 patients’ tumors with targeted agents and immunotherapies in early clinical trials over the last 8 years

Background: Since 2010, when the Molecular Prescreening Program (MPP) was established at VHIO, we have adapted the techniques and procedures to improve the identification of genomic alterations in tumors from patients (pts) eligible to Early Clinical Trials (ECTs). Here we report the clinical utility of our program given the evolving molecular testing landscape and trends in drug development.